RAPT Therapeutics, Inc. Stock News

RAPT Therapeutics' lead candidate, zelnecirnon, is in phase 2 for atopic dermatitis and asthma with very promising ph1b results in atopic dermatitis and potential expansion in multiple indications. Li

The heavy selling pressure might have exhausted for Rapt Therapeutics (RAPT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street a

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and com

- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease - Confirmed ORR of 22.2% in subs

It is not a bad idea to hunt for biotech stocks to sell. Such stocks have earned a bad reputation among investors, and for good reason.

NEW YORK, March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT).  Such investors are advis

RAPT Therapeutics (RAPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and c

Includes late-breaking poster presentation to highlight phase 2 clinical data for tivumecirnon in head and neck cancer Includes late-breaking poster presentation to highlight phase 2 clinical data for

NEW YORK , March 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT).  Such investors are advised

NEW YORK--(BUSINESS WIRE)---- $RAPT #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RAPT Therapeutics, Inc. (“RAPT

Biotech stock Rapt plummeted to a record low Tuesday after the Food and Drug Administration put two of its clinical studies on hold.

RAPT Therapeutics Inc. shares RAPT, +1.68% dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its experimental inflammation treatment

- RAPT to host a conference call today at 8:30 am ET - SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biophar

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and co